AC
BMRN icon

Alexandria Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alexandria Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26
Closed -$2K – 268
2017
Q3 		$2K Sell
26
-43
-62% -$3.8K ﹤0.01% 500
2017
Q2 		$6K Sell
69
-14
-17% -$1.27K ﹤0.01% 463
2017
Q1 		$7K Sell
83
-4
-5% -$356 ﹤0.01% 449
2016
Q4 		$7K Buy
87
+9
+12% +$774 ﹤0.01% 446
2016
Q3 		$7K Buy
78
+23
+42% +$2.17K ﹤0.01% 450
2016
Q2 		$4K Buy
55
+18
+49% +$1.53K ﹤0.01% 495
2016
Q1 		$3K Buy
37
+10
+37% +$814 ﹤0.01% 528
2015
Q4 		$3K Buy
27
+13
+93% +$1.36K ﹤0.01% 573
2015
Q3 		$1K Buy
+14
New +$1.87K ﹤0.01% 563

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return